CommentConsidering benefit and risk before routinely recommending SpaceOAR
References (10)
- et al.
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
Lancet Oncol
(2016) - et al.
Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial
Int J Radiat Oncol Biol Phys
(2017) - et al.
Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy
Int J Radiat Oncol Biol Phys
(2015) - et al.
Evaluating the cost-effectiveness of hydrogel rectal spacer in prostate cancer radiation therapy
Pract Radiat Oncol
(2019) - et al.
Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG oncology RTOG 0126 randomized clinical trial
JAMA Oncol
(2018)
Cited by (22)
AUA/ASTRO 2022 Guidelines: “Scrutinized”
2023, Practical Radiation OncologyA case report: Retrograde arterial embolization of locally-injected SpaceOAR hydrogel material into the right common iliac artery bifurcation
2023, Radiology Case ReportsCitation Excerpt :SpaceOAR is a biodegradable hydrogel matrix developed for protecting the rectum against iatrogenic radiation injury during prostate cancer radiation therapy [1–3].
Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group
2022, Critical Reviews in Oncology/HematologyCitation Excerpt :It is a rather safe and minimally invasive procedure that allows a significant decrease of the dose to the rectum (Chapet et al., 2014; Boissier et al., 2017). As such, it can be considered an option before prostate SBRT, although some authors have expressed reservations about general applicability (Hall et al., 2021). We recommend that the bladder be delineated as a full organ as well.
Characterization of an Iodinated Rectal Spacer for Prostate Photon and Proton Radiation Therapy
2022, Practical Radiation OncologyCitation Excerpt :Since that time, use of the perirectal spacer for prostate radiation therapy has increased, with exploration of its use in different radiation therapy techniques including stereotactic body radiation therapy (SBRT) and brachytherapy.4-11 Use of the perirectal spacer is not without any associated toxicity, as a recent analysis using the Food and Drug Administration Manufacturer and User Facility Device database described 85 reported events between May 2015 and May 2020, 69% of which were Common Terminology Criteria for Adverse Events (version 5.0) grade 3, 4, or 5.12 Although severe events are rare, the recommendation for use of a perirectal spacer in a patient with prostate cancer requires a balanced discussion surrounding the potential benefits and outlining possible risks associated with its placement/use.